These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11158863)

  • 1. Control of secondary hyperparathyroidism by vitamin D derivatives.
    Drüeke TB
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S58-61. PubMed ID: 11158863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D analogs: perspectives for treatment.
    Brown AJ; Slatopolsky E
    Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical management of secondary hyperparathyroidism in uremia.
    Drüeke TB
    Am J Med Sci; 1999 Jun; 317(6):383-9. PubMed ID: 10372838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D analogues for secondary hyperparathyroidism.
    Brown AJ; Dusso AS; Slatopolsky E
    Nephrol Dial Transplant; 2002; 17 Suppl 10():10-9. PubMed ID: 12386264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
    Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
    G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of renal osteodystrophy in predialysis patients.
    Sanchez CP; Goodman WG; Salusky IB
    Am J Med Sci; 1999 Jun; 317(6):398-404. PubMed ID: 10372840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D metabolites and/or analogs: which D for which patient?
    Mazzaferro S; Goldsmith D; Larsson TE; Massy ZA; Cozzolino M
    Curr Vasc Pharmacol; 2014 Mar; 12(2):339-49. PubMed ID: 23713876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
    J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D and its analogs in chronic renal failure.
    Slatopolsky E; Brown AJ
    Osteoporos Int; 1997; 7 Suppl 3():S202-8. PubMed ID: 9536333
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
    Drüeke TB
    Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcimimetics versus vitamin D: what are their relative roles?
    Drüeke TB
    Blood Purif; 2004; 22(1):38-43. PubMed ID: 14732810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of vitamin D analogs in chronic renal failure.
    Kim G; Sprague SM
    Adv Ren Replace Ther; 2002 Jul; 9(3):175-83. PubMed ID: 12203199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
    Brown AJ; Coyne DW
    Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.